Ejaculation

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

September is Prostate Cancer Awareness Month: Know the Warning Signs, When to Get Screened and Important New Treatments

Retrieved on: 
Wednesday, August 30, 2023

ATLANTA, Aug. 30, 2023 /PRNewswire/ -- Prostate cancer is the second leading cause of cancer death among men in the United States. According to the latest research from scientists at the American Cancer Society (ACS), more than 288,000 men will be diagnosed with the disease this year, with close to 35,000 deaths. Black men are two times more likely to die from the disease than White men and have the highest death rate for prostate cancer of any racial and ethnic group. However, when prostate cancer is detected early, the odds of survival are high. In fact, more than 3.5 million men diagnosed with the disease in the U.S. are still alive today.

Key Points: 
  • Renowned prostate cancer researcher Dr. Lorelei Mucci is the director of strategic research partnerships at the American Cancer Society.
  • Her role includes leading an ACS initiative called IMPACT , or "Improving Mortality Toward Prostate Cancer Together" to address the alarming negative trends in prostate cancer incidence and disparities.
  • For Prostate Cancer Awareness Month Dr. Mucci reviews the signs and symptoms of prostate cancer, including important information about risk factors, PSA screening, and more:
    1-Why is it important every September during Prostate Cancer Awareness Month to help people learn about the disease?
  • Prostate Cancer Awareness Month is so important to have a focused time for men and their families to share knowledge, experiences, and state of science on this important cancer.

Nymox Reports on U.S. Patent Issuances

Retrieved on: 
Tuesday, July 18, 2023

IRVINE, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.

Key Points: 
  • IRVINE, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.
  • The Company continues to expand its patent portfolio, which is an integral part of its business.
  • In the past 18 months, numerous newly issued patents have been granted in important jurisdictions in different parts of the world, including major markets.
  • The Company's CEO and founder, Paul Averback has been the inventor responsible for the Company's technology and patents.

Nymox Update

Retrieved on: 
Thursday, July 13, 2023

IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.

Key Points: 
  • IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.
  • Nymox recently terminated the employment of Mr. Randall Lanham, the Company’s former in-house legal counsel, and Mr. Christopher Riley, the Company’s former chief financial officer.
  • Mr. Lanham (legal counsel) and Mr. Riley (CFO) previously presented Nymox with a transaction with a potential business partner (the “Proposed Transaction”).
  • Dr. Paul Averback, CEO of Nymox said, "Our fiduciary responsibilities are first and foremost to the shareholders of Nymox, and the above terms were not in the best interests of Nymox shareholders.

Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox

Retrieved on: 
Wednesday, July 12, 2023

IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.

Key Points: 
  • IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.
  • Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel.
  • Mr. Doody has represented Nymox and its predecessor company in intellectual property matters for over 30 years, securing hundreds of issued patents for Nymox throughout the world.
  • Dr. Paul Averback CEO and Chairman of Nymox said, "Patrick brings with him decades of experience with industry and in legal intellectual property practice.

NYMOX Update

Retrieved on: 
Friday, July 7, 2023

IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management.

Key Points: 
  • IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management.
  • Two former employees (the “Former Employees”) of the Company proposed to the Company a potential transaction (the “Proposed Transaction”).
  • The Company, its employees, and the Former Employees are bound by an obligation not to disclose any details of the Proposed Transaction.
  • Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH).

Nymox Delisting from NASDAQ

Retrieved on: 
Wednesday, July 5, 2023

Dr. Paul Averback, CEO of Nymox said, "This is a key time for the Company, with more than one important marketing application being submitted. We are grateful to our loyal shareholders for their patience and we wish to assure our supporters that we are doing our best to deliver important milestones in our business development, in as reasonable a time horizon as possible. It took a long time to get to this point but we believe enhanced fundamental value has been developed -- and we intend to continue to do everything in our power to deliver the goods to the public and to our stakeholders."

Key Points: 
  • IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023.
  • Nymox shares will be moved to the OTC market.
  • Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH).
  • Dr. Paul Averback, CEO of Nymox said, "This is a key time for the Company, with more than one important marketing application being submitted.

Olympus Announces Launch of Next Generation Electrosurgical Generator

Retrieved on: 
Tuesday, June 6, 2023

The ESG-410 Electrosurgical Generator, with its accessories and ancillary equipment, is intended for cutting and coagulation of tissue in open, laparoscopic and endoscopic surgery and should only be used by a qualified physician in an adequate medical environment.

Key Points: 
  • The ESG-410 Electrosurgical Generator, with its accessories and ancillary equipment, is intended for cutting and coagulation of tissue in open, laparoscopic and endoscopic surgery and should only be used by a qualified physician in an adequate medical environment.
  • Improper use or use of incompatible equipment with this electrosurgical generator can lead to excessive or incorrect HF and cause thermal or other injuries for the patient and/or operator.
  • Be aware that if the mains plug is accidentally disconnected during a procedure, the electrosurgical generator immediately turns off and this can result in complications for the patient.
  • At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling.

Women's Pelvic Health: Top 10 Things Women Want to Know about Sex and Vaginal Health but Are Reluctant to Ask

Retrieved on: 
Tuesday, May 16, 2023

ATLANTA, May 16, 2023 /PRNewswire/ -- Committed to helping healthcare providers elevate the care of women at midlife and beyond, Solv Wellness regularly hosts webinars that enable peer-to-peer knowledge sharing. During their latest free educational webinar for providers, Brooke Faught, DNP, WHNP-BC, NCMP, FAANP, IF, and member of the Solv Wellness medical advisory board, emphasized the importance of driving conversations about sex and pelvic health with their patients to ensure women are not suffering in silence, especially with the broad availability of safe and effective solutions.

Key Points: 
  • It's so important, and we can even identify a lot of serious health concerns based on sexual symptoms and sexual complications."
  • In the webinar, Dr. Faught covered a variety of often-ignored topics about women's pelvic health.
  • She hopes sharing her experience will help foster more open dialogue between patients and their healthcare providers during office visits.
  • First, it's important to determine what's causing lack of interest in sex: low libido or hypoactive sexual desire disorder (HSDD).

Urologists Explore Online Educational Content, Erectile Dysfunction Drug Choices and Physical Therapy to Treat Premature Ejaculation

Retrieved on: 
Friday, April 28, 2023

Are there meaningful differences in drug choice for men with coronary artery disease and erectile dysfunction?

Key Points: 
  • Are there meaningful differences in drug choice for men with coronary artery disease and erectile dysfunction?
  • Researchers will be presenting these sexual health study findings at the 118th Annual Scientific Meeting of the American Urological Association.
  • "Long term follow-up outcomes of pelvic floor rehabilitation in subjects suffering from lifelong premature ejaculation: retrospective multicentre study."
  • Highlights include a study showing commonly prescribed erectile dysfunction treatments reduce life-threatening cardiovascular diseases, and another study utilizing physical therapy to treat premature ejaculation," said Dr. Bajic.